• X-Gal A2539: Reliable β-Galactosidase Workflows

  2026-08-28

  Learn how X-Gal (SKU A2539) supports controlled blue-white colony screening and β-galactosidase activity assays while avoiding common errors in viability and proliferation data interpretation. This scenario-based guide covers assay compatibility, preparation, controls, data limits, and practical product-selection criteria.

• SN-38 Disrupts FUBP1–FUSE DNA Binding

  2026-08-28

  The reference study identifies camptothecin and SN-38 as inhibitors of the interaction between the oncogenic transcriptional regulator FUBP1 and its single-stranded DNA target, FUSE. By combining a compound-library screen, AlphaScreen-based binding assays, and cellular gene-expression analysis, the work proposes FUBP1/FUSE disruption as a mechanism that may complement topoisomerase I inhibition.

• CLCC1 Promotes Herpesvirus Nuclear Egress

  2026-08-27

  The reference preprint identifies the host protein CLCC1 as an essential factor in the membrane-fusion step that releases herpesvirus capsids from the nucleus. Its CRISPR-screen and cell-biological evidence connect herpesvirus nuclear egress with nuclear pore insertion and broader nuclear-envelope morphogenesis, while also defining important limits for therapeutic interpretation.

• Mdivi-1 Workflows for Mitochondrial Fission Studies

  2026-08-27

  Mdivi-1 provides a rapid, reversible way to test whether DRP1-dependent mitochondrial fission contributes to apoptosis, stress signaling, or retinal injury. This workflow connects mitochondrial morphology with functional and immune readouts, including the ECM-to-mitochondria pathway described in recent Cell research.

• O6-Benzylguanine: Reliable MGMT Assay Workflows

  2026-08-26

  A scenario-based guide to using O6-Benzylguanine as an MGMT inhibitor in viability, proliferation, and alkylator-sensitization assays. It explains formulation, controls, interpretation, and why SKU B5974 supports reproducible cancer chemotherapy research.

• Dasatinib Monohydrate in CML NET Research

  2026-08-26

  Use Dasatinib Monohydrate as a precisely controlled kinase perturbation in chronic myeloid leukemia research, pairing BCR-ABL pathway readouts with neutrophil extracellular trap measurements. This workflow helps distinguish direct antileukemic activity from TKI-specific effects on NET biology, oxidative stress, and vascular-risk mechanisms.

• Phytol Workflows for RXR Signaling Studies

  2026-08-25

  Phytol supports a practical, tiered strategy for studying RXR-driven transcription, PPARα-linked metabolism, and GABAergic transmission modulation. This guide combines solvent-aware dosing, isomer and purity controls, orthogonal readouts, and a disciplined experimental-design lesson from polymer self-assembly research.

• Topotecan Pharmacology and Clinical Evidence

  2026-08-25

  The 1999 review by Kollmannsberger and colleagues synthesized the pharmacology, dosing, toxicity, and early clinical evidence for topotecan, a water-soluble camptothecin analogue that inhibits topoisomerase I. Its analysis established how lactone–carboxylate chemistry, renal elimination, schedule selection, and limited cross-resistance shaped the clinical development of this DNA-damaging agent.

• Alfuzosin HCl in BPH: Mechanism and Evidence

  2026-08-24

  Mary Lee’s clinical review interprets alfuzosin as a functionally uroselective α1 adrenoceptor antagonist whose therapeutic value arises from relaxing prostatic and bladder outlet smooth muscle while limiting clinically important cardiovascular effects. Its central contribution is the integration of receptor pharmacology, pharmacokinetics, immediate- versus extended-release formulation behavior, clinical efficacy, and quality-of-life outcomes into a translational framework for benign prostatic hyperplasia research.

• Nutlin-3a Workflows for MDM2-p53 Cancer Research

  2026-08-23

  Nutlin-3a is a practical MDM2 inhibitor for controlled p53 pathway activation, dose-response profiling, and mechanistic studies of cell cycle arrest and apoptosis induction. This workflow connects reproducible compound handling with glioblastoma assays that distinguish apoptosis from ferroptosis and migration effects.

• Fenofibrate in PPARα Signaling Research

  2026-08-22

  Fenofibrate is a practical PPARα agonist for connecting lipid metabolism, YAP activity, liver remodeling, and cancer-cell phenotypes in one research strategy. This guide translates the latest aging-mouse evidence into reproducible cell, tissue, and in vivo workflows with formulation and troubleshooting guidance.

• Maternal Deltamethrin Exposure and Hippocampal Ferroptosis

  2026-08-21

  The 2025 reference study links maternal deltamethrin exposure with impaired learning and memory in male rat offspring through p53-associated ferroptosis in the hippocampus. Its integrated behavioral, histological, biochemical, and cell-based design implicates the p53–SLC7A11/GPX4 axis and disrupted calcium signaling as mechanistic targets for developmental neurotoxicology.

• BIBP 3226 Trifluoroacetate: Assay Strategy

  2026-08-21

  BIBP 3226 trifluoroacetate is a mechanistically informative antagonist for separating NPY Y1 and NPFF signaling. This guide translates adipose-neural cardiac arrhythmia findings into practical receptor, cAMP, and coculture assay decisions.

• Reserpine (N1867): Practical Lab Workflow

  2026-08-20

  Reserpine (SKU N1867) provides a defined research material for neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows where solvent compatibility and fresh-solution handling are important. It is intended for controlled laboratory research only, not for diagnostic, clinical, therapeutic, or veterinary use.

• Verapamil: A Temporal Probe of Hypoxic Inflammation

  2026-08-20

  Verapamil ((±)-Verapamil) can do more than block calcium influx: in urothelial hypoxia models, it helps test whether inflammation depends on exposure duration and ROS-linked TXNIP/NLRP3 signaling. This article translates the evidence into a causal assay framework while defining the compound’s mechanistic and experimental limits.

459 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page